Craft

Elanix Biotechnologies

Stock Price

€0.1

2023-08-04

Market Capitalization

€6 M

2023-08-02

Revenue

€62 K

FY, 2018

Elanix Biotechnologies Summary

Company Summary

Overview
Elanix Biotechnologies develops and commercializes products for acute wound care, dermatological and gynecological applications. The company develops and markets progenitor cell-based products that are used to regenerate tissue and promote healing in the treatment of burns, and gynecological and dermatological conditions. Its products include GYNrepair, a cream for genital external mucosa, and SKINrepair, a cream for skin that protects against external aggressions. Elanix Biotechnologies is also developing FirstCover, an acute wound care tissue engineering product that is used to provide protection and healing for burns, and trauma and plastic surgery. The company offers cell technology services as well. 
Type
Public
Status
Closed
Founded
2012
HQ
Frankfurt am Main, DE | view all locations
Website
https://www.elanixbiotechnologies.ch/
Cybersecurity rating
Sectors

Key People

  • Tomas J. Svoboda, CEO

    LocationsView all

    3 locations detected

    • Frankfurt am Main, HE HQ

      Germany

      Hanauer Landstraße 291B

    • Epalinges, VD

      Switzerland

      Route de la Corniche 4

    • Nyon, Vaud

      Switzerland

      10 Chemin du Joran

    Elanix Biotechnologies Financials

    Summary Financials

    Revenue (H1, 2019)
    €3.0K
    Gross profit (H1, 2019)
    €103.0K
    Net income (H1, 2019)
    (€609.0K)
    Cash (H1, 2019)
    €39.0K
    EBIT (H1, 2019)
    (€213.0K)
    Enterprise value
    $5.9M

    Footer menu